Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase

Patent Citations (68)

Non-Patent Literature (76)

• International Search Report for International Application No. PCT/US2004/035083.Applicant
• Ballatore, C., et al., “Synthesis and Evaluation of Novel Amidate Prodrugs of PMEA and PMPA”, Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 11, 2001, pp. 1053-1056.Applicant
• International Search Report for International Application No. PCT/US2004/035084.Applicant
• International Search Report for International Application No. PCT/US2004/035085.Applicant
• Siddiqui, A. Q., et al., “Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR”, Journal of Medicinal Chemistry, American Chemical Society, Washington, DC, vol. 42, No. 20, 1999, pp. 4122-4128.Applicant
• Tan, Fulong, et al., “Sequencing and Cloning of Human Prolylcarboxypeptidase (Angiotensinase C): Similarity to Both Serine Carboxypeptidase and Prolylendopeptidase Families”, Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, vol. 268, No. 22, 1993, pp. 16631-16638.Applicant
• Valette, G. et al., “Decomposition Pathways and in Vitro HIV Inhibitory Effects of IsoddA Pronucleotides: Toward a Rational Approach for Intracellular Delivery of Nucleoside 5′- Monophosphates”, Journal of Medicinal Chemistry, American Chemical Society, Washington, DC, vol. 39, No. 10, 1996, pp. 1981-1990.Applicant
• Abdel-Meguid et al., “Inhibition of Human Immunodeficiency Virus-1 Protease by a C2-Symmetric Phosphinate. Synthesis and Crystallographic Analysis”, Biochemistry, 32(31):7972-7980 (1993).Applicant
• Allen et al., “CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK)”, Seminars in Oncology, 30(5, Suppl. 16):105-116 (2003).Applicant
• Andrade et al., “HIV-Related Drug Metabolism and Cytochrome P450 Enzymes” AIDS Clinical Care, 12(11):91-95 (2000).Applicant
• Bantia et al., “Purine Nucleoside Phosphorylase Inhibitor BCX-1777 (Immucillin-H)—A Novel Potent and Orally Active Immunosuppressive Agent”, International Immunopharmacology, 1:1199-1210 (2001).Applicant
• Beauchamp, et al., “Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase”, Journal of Medicinal Chemistry, 39:949-956 (1996).Applicant
• Borhani et al., “A-420983: A Potent, Orally Active Inhibitor of 1ck with Efficacy in a Model of Transplant Rejection”, Bioorganic & Medicinal Chemistry Letters, 14:2613-2616 (2004).Applicant
• Bzowska et al., “Purine Nucleoside Phosphorylases: Properties, Functions, and Clinical Aspects”, Pharmacology & Therapeutics, 88:349-425 (2000).Applicant
• Chapman et al., “Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340”, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7):621-628 (2001).Applicant
• Charvet et al., “Inhibition of Human Immunodeficiency Virus Type I Replication by Phosphonoformate- and Phosphonoacetate-2′,3′-Dideoxy-3′-thiacytidine Conjugates”, Journal of Medicinal Chemistry, 37(14):2216-2223 (1994).Applicant
• Clark et al., Abstract, “Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection”, Institute for Antiviral Research, Utah State University.Applicant
• Conklyn et al., “The JAK3 Inhibitor CP-690550 Selectively Reduces NK and CD8+ Cell Numbers in Cynomolgus Monkey Blood Following Chronic Oral Dosing”, Journal of Leukocyte Biology, 76:1-8 (2004).Applicant
• De Clercq, “Chemotherapy of Human Immunodeficiency Virus (HIV) Infection: Anti-HIV Agents Targeted at Early Stages in the Virus Replicative Cycle”, Biomedicine and Pharmacotherapy, 50(5):207-215 (1996).Applicant
• De Clercq, “Highlights in the Development of New Antiviral Agents”, Mini Reviews in Medicinal Chemistry, 2(2):163-175 (2002).Applicant
• De Clercq, “New Developments in Anti-HIV Chemotherapy”, Current Medicinal Chemistry, 8(13):1543-1572 (2001).Applicant
• Dvo{hacek over (r)}áková et al., “Synthesis of 2′-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents”, J. Med. Chem., 39(17):3263-3268 (1996).Applicant
• Eisenberg et al., “Metabolism of GS-7340, a Novel Phenyl Monophosphoramidate Intracellular Prodrug of PMPA, in Blood”, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7):1091-1098 (2001).Applicant
• Evans et al., “Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase”, J. Med. Chem., 46(15):3412-3423 (2003).Applicant
• Gobec et al., Phosphonate Inhibitors of Antigen 85C, a Crucial Enzyme Involved in the Biosynthesis of the Mycobacterium tuberculosis Cell Wall, Bioorganic and Medicinal Chemistry Letters, 14:3559-3562 (2004).Applicant
• Gorin et al., “A Novel Esterification Procedure Applied to Synthesis of Biologically Active Esters of Foscarnet”, Tetrahedron Letters, 38(16):2791-2794 (1997).Applicant
• Gumina et al., “Advances in antiviral agents for Hepatitis B Virus”, Antiviral Chemistry & Chemotherapy, 12(Suppl. 1):93-117 (2001).Applicant
• Hakimelahi et al., “Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses”, Journal of Medicinal Chemistry, 38(23):4648-4659 (1995).Applicant
• Hammond et al., “Alkylglycerol Prodrugs of Phosphonoformate are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations that Suppress Zidovudine Resistance”, Antimicrobial Agents and Chemotherapy, 45(6):1621-1628 (2001).Applicant
• Hegedus et al., “Synthesis of 4′-Methyl and 4′-Cyano Carbocyclic 2′,3′-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones”, J. Org. Chem., 69(24):8492-8495 (2004).Applicant
• Herczegh et al., “Osteoadsorptive Biphosphonate Derivatives of Fluoroquinolone Antibacterials”, J. Med. Chem., 45:2338-2341 (2002).Applicant
• Hirabayashi et al., “Bone-Specific Drug Delivery Systems: Approaches via Chemical Modification of Bone-Seeking Agents”, Clinical Pharmacokinetics, 42(15):1319-1330 (2003).Applicant
• Holý et al., “Synthesis of N-(2-Phosphonylmethoxyethyl Derivatives of Heterocyclic Bases”, Collect. Czech. Chem. Commun., 54:2190-2210 (1989).Applicant
• International Search Report for International Application No. PCT/EP2003/012423, mailed Feb. 11, 2005.Applicant
• International Search Report for International Application No. PCT/US2004/042991, mailed Jun. 6, 2005.Applicant
• Jain et al., “Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor”, Journal of Pharmacology and Experimental Therapeutics, 302(3):1272-1277 (2002).Applicant
• Karpenko et al., “Synthesis and Antiherpetic Activity of Acyclovir Phosphonates”, Nucleosides, Nucleotides & Nucleic Acids, 22(3):319-328 (2003).Applicant
• Kato et al., “Enantio- and Diastereoselective Synthesis of 4′-α-Substituted Carbocyclic Nucleosides”, Tetrahedron: Asymmetry, 9:911-914 (1998).Applicant
• Kato et al., “Stereoselective Synthesis of 4′ -α-alkylcarbovir Derivatives Based on an Asymmetric Synthesis or Chemo-Enzymatic Procedure”, Chemical & Pharmaceutical Bulletin, 47(9):1256-1264 (1999).Applicant
• Kilpatrick et al., “Intravenous and Oral Pharmacokinetic Study of BCX-1777, a Novel Purine Nucleoside Phosphorylase Transition-State Inhibitor, In vivo Effects on Blood 2′-Deoxyguanosine in Primates”, International Immunopharmacology, 3:541-548 (2003).Applicant
• Kim et al., “Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity Against HIV”, J. Org. Chem., 56(8):2642-2647 (1991).Applicant
• Kinsky et al., “Inhibition of Cell Proliferation by Putative Metabolites and Non-Degradable Analogs of Methotrexate-γ-Dimyristoylphosphatidylethanolamine”, Biochimica et Biphysica Acta, 917(2):211-218 (1987).Applicant
• Kinsky et al., “Effect of Liposomes Sentitized with Methotrexate-γ-Dimyristoylphosphatidylethanolamine on Cells that are Resistant to Methotrexate”, Biochimica et Biophysica Acta, 885:129-135 (1986).Applicant
• Kinsky et al., “Circumvention of the Methotrexate Transport System by Methotrexate-Phosphatidylethanolamine Derivatives Effect of Fatty Acid Chain Length”, Biochimica et Biophysica Acta, 921:96-103 (1987).Applicant
• Ko et al., “Efficient Synthesis of Novel Carbocyclic Nucleosides via Sequential Claisen Rearrangement and Ring-Closing Metathesis”, Tetrahedron Letters, 43:6399-6402 (2002).Applicant
• Kofoed et al., “Regiosomers of 2′,3′-Dideoxynucleosides Related to 2-(Phosphonylmethoxy)ethyl Nucleosides”, Bulletin de la Societe Chimique de France, 134:59-65 (1997).Applicant
• Kraus, “New Phosphonate Analogues of 3′-thia-2′,3′-Dideoxycytidine (BCH-189) Synthesis and Anti-HIV Evaluation”, Nucleosides & Nucleotides, 12(2):157-162 (1993).Applicant
• Leff et al., “The Antidiabetic PPARγ Ligands: An Update on Compounds in Development”, Curr. Med. Chem.-Imun., Endoc. & Metab. Agents 2(1):33-47 (2002).Applicant
• Lewandowicz et al., “Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase”, The Journal of Biological Chemistry, 278(34):31465-31468 (2003).Applicant
• McGuigan et al., “Synthesis and Anti-HIV Activity of Some Novel Chain-Extended Phosphoramidate Derivatives of d4T (Stavudine): Esterase Hydrolysis as a Rapid Predictive Test for Antiviral Potency”, Antiviral Chemistry & Chemotherapy, 9:109-115 (1998).Applicant
• McGuigan et al., Synthesis, Anti-Human Immunodeficiency Virus Activity and Esterase Lability of Some Novel Carboxylic Ester-Modified Phosphoramidate Derivatives of Stavudine (d4T), Antiviral Chemistry & Chemotherapy, 9:473-479 (1998).Applicant
• Mendes et al., “Synthesis, Stability and In Vitro Dermal Evaluation of Aminocarbonyloxymethyl Esters as Prodrugs of Carboxylic Acid Agents”, Bioorganic & Medicinal Chemistry, 10(3):809-816 (2002).Applicant
• Menéndez-Arias, “Targeting HIV: Antiretroviral Therapy and Development of Drug Resistance”, TRENDS in Pharmacological Sciences, 23(8):381-388 (2002).Applicant
• Ono-Nita et al., “Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective Against Wild-Type or Lamivudine-Resistant Hepatitis B Virus”, Antimicrobial Agents and Chemotherapy, 46(8):2602-2605 (2002).Applicant
• Pankiewicz et al., “Novel Mycophenolic Adenine Bis(phosphonate) Analogues As Potential Differentiation Agents Against Human Leukemia”, J. Med. Chem., 45(3):703-712 (2002).Applicant
• Parang et al., “Novel Approaches for Designing 5′-O-Ester Prodrugs of 3′-Azido-2′, 3′-Dideoxythymidine (AZT)”, Current Medicinal Chemistry, 7(10):995-1039 (2000).Applicant
• Pokrovskii et al, “Comparative Analysis of HIV-1 Resistance to AZT and AZT H-Phosphonate in a Cell Culture”, Doklady Biochemistry and Biophysics, 384:152-154 (2002).Applicant
• Prashad et al., “An Efficient and Large-Scale Enantioselective Synthesis of PNP405: A Purine Nucleoside Phosphorylase Inhibitor”, J. Org. Chem., 67(19):6612-6617 (2002).Applicant
• Ray et al., “Role of Purine Nucleoside Phosphorylase in Interactions between 2′, 3′-Dideoxyinosine and Allopurinal, Ganciclovir, or Tenofovir”, Antimicrobial Agents and Chemotherapy, 48(4):1089-1095 (2004).Applicant
• Roberts, “Development of the Route to the New Anti-AIDS drug Abacavir: A highlight of Academic/Industry Liaison”, IDrugs, 1(8):896-899 (1998).Applicant
• Rosowsky et al., “Methotrexate Analogues—27”, Biochemical Pharmacology, 35(19):3327-3333 (1986).Applicant
• Rosowsky et al., “Methotrexate Analogues, 32, Chain Extension, α-Carboxyl Deletion, and γ-Carboxyl Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth Inhibition”, J. Med. Chem., 31(7):1326-1331 (1988).Applicant
• Saboulard et al., “Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of Stavudine and Zidovudine”, Molecular Pharmacology, 56:693-704 (1999).Applicant
• Sauber et al., “A New Esterase for the Cleavage of Pivalic Acid-Containing Prodrug Esters of Cephalosporins”, Enzyme and Microbial Technology, 19:15-19 (1996).Applicant
• Schultz, “Prodrugs of Biologically Active Phosphate Esters”, Bioorganic & Medicinal Chemistry, 11:885-898 (2003).Applicant
• Sekiya et al., “2-Amino-6-Arylthio-9-[2-(Phosphonomethoxy) Ethyl) Purine Bis(2,2,2-Trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents”, Journal of Medicinal Chemistry, 45(14):3138-3142 (2002).Applicant
• Shi et al., “Plasmodium falciparum Purine Nucleoside Phosphorylase”, The Journal of Biological Chemistry, 279(18):18103-18106 (2004).Applicant
• Sintchak et al., “The Structure of Inosine 5′-Monophosphate Dehydrogenase and the Design of Novel Inhibitors” Immunopharmachology, 47:163-184 (2000).Applicant
• Srinivas et al., “Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates”, Antimicrobial Agents and Chemotherapy, 37(10):2247-2250 (1993).Applicant
• Sturtz et al., “Sur une nouvelle Approche de Pharmacomodulation du Methotrexate: Synthese D'analogues Gem-Diphosphoniques D'amethopterine et de la N-10 Deaza Amethopterine”, Medicinal Chemistry, C. R. Acad. Sci. Paris, 10(2):739-742 (1990).Applicant
• Sturtz et al., “Analogues Phosphonoglutamiques D'amethopterine (Methotrexate)”, Eur. J. Med. Chem—Chim. Ther., 19(3):267-273 (1984).Applicant
• Sturtz et al., “Synthesis of Gem-Bisphosphonic Methotrexate Conjugates and Their Biological Response Towards Walker's Osteosarcoma”, Eur. J. Med. Chem., 28:899-903 (1993).Applicant
• Sturtz et al., “A Study of the Delivery-Targeting Concept Applied to Antineoplasic Drugs Active on Human Osteosarcoma, I. Synthesis and Biological Activity in Nude Mice Carrying Human Osteosarcoma Xenografts of Gem-Bisphosphonic Methotrexate Analogues”, Eur. J. Med. Chem., 27(8):825-833 (1992).Applicant
• Vielhaber, “Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection”, Deutsche Aids-Hilfe e.V. Fax Report zu HIV und AIDS, Seite 4 (2000).Applicant
• Waegall et al., “A420983, a Novel, Small Molecule Inhibitor of LCK Prevents Allograft Rejection”, Transplantation Proceedings, 34:1411-1417 (2002).Applicant
• Wróblewski et al., Synthesis of (1R,2S)- and (1S,2S)-3-(4-Carbamoyl-1,2,3-triazol-1-yl)-1,2-Dihydroxypropylphosphonates, Tetrahedron: Asymmetry, 15:1457-1464 (2004).Applicant